The IMPACT trial shows Pulmonx Corp.'s Zephyr endobronchial valves produces clinically meaningful benefits in improved lung function, exercise tolerance and quality-of-life for patients with homogenous emphysema without collateral ventilation who were selected for the therapy with Pulmonx' Chartis diagnostic tool.
Results of the 93-patient IMPACT trial, led by Arschang Valipour of the Ludwig Boltzmann-Institute in Vienna, are published online in the American Journal of Respiratory and Critical Care Medicine
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?